Replies to post #29588 on Ocata Therapeutics Inc fka OCAT

[rocky301]

harlem,

as I posted to you yesterday, they changed the verbage.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=60097755

We have always known the NIH cell lines were Single blastomere derived..the upcoming patent is for a METHOD to obtain the hESC cells(without harming embryo)....

From a year ago,
That change would allow ACT's five single-blastomere lines currently under review at the NIH to receive federal funding for research, if approved by the agency. ACT currently has an investigational new drug application (IND) under review at the FDA for a Phase I/II trial using its MA09 single-blastomere line to treat Stargardt disease, a genetic condition and the leading cause of juvenile blindness in the U.S., Lanza told BioWorld Today.